Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 17 trials
But theyre also a reminder of what sustained investment in basic science can achieve. As UAB researchers continue to study how these drugs work and what comes next, their findings are helping move the conversation beyond hype, while working toward a clearer understanding of one of the most significant medical breakthroughs of the past decade.
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
A systematic review of 26 studies including 3020 participants showed mixed and inconclusive effects of GLP-1 RAs on psychiatric symptoms
Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss
US$ 22.20
US$ 20.04
US$ 29.21
US$ 27.38
